IBOV 167,927.15 ▲ 0.06% IPSA 11,237.90 ▼ 0.03% IPC MEX 64,436.38 ▲ 0.68% MERVAL 2,875,950 ▲ 0.05% COLCAP 2,444.32 ▼ 0.39% BVL PERÚ 58,380.78 ▲ 0.54% USD/BRL5.19▲ 0.34% USD/MXN16.94▼ 0.03% USD/CLP922.13▲ 0.08% USD/COP3,063▼ 1.39% USD/PEN3.35▼ 0.52% USD/ARS1,497▼ 0.02% USD/UYU40.21▲ 0.95% USD/PYG5,992▲ 1.19% USD/BOB11.42▲ 0.14% USD/DOP58.82▲ 1.31% USD/CRC446.30▲ 2.09% USD/GTQ7.62▲ 2.24% USD/HNL26.81▲ 1.60% USD/NIO36.62▲ 0.69% USD/VES775.47▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.71▲ 0.93% EUR/BRL6.06▲ 0.55% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 167,927.15 ▲ 0.06% IPSA 11,237.90 ▼ 0.03% IPC MEX 64,436.38 ▲ 0.68% MERVAL 2,875,950 ▲ 0.05% COLCAP 2,444.32 ▼ 0.39% BVL PERÚ 58,380.78 ▲ 0.54% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Thursday, August 20, 2026

Covid-19 Brazil

Brazilian court fines Covid-19 early treatment advocates US$11 million

By · May 26, 2023 · 3 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

The Federal Court of Rio Grande do Sul sentenced the advocates of early treatment against Covid-19 to a fine of R$55 million (US$11 million) for collective moral damage to health.

The decision was released this Thursday (25) by the Federal Public Ministry (MPF).

The prosecution filed two lawsuits against the group Doctors for Life and the companies Vitamedic Pharmaceuticals, Alves Faria Educational Center, and the José Alves Group (GJA Participações).

The MPF claims that the group, which identified itself as “Brazili’s doctors of early treatment”, encouraged the consumption of drugs supposedly without proven effectiveness that would be part of an “early treatment”, and encouraged self-medication.

Hydroxychloroquine was among the drugs in the so-called “Covid Kit” (Photo internet reproduction)
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

The material was advertised to the general population under the title “Covid Kit”, contrary to the legislation and normative act of the National Health Regulation Agency (Anvisa) that deals with the advertising and publicity of medicines.

In the Court’s decision, the collaboration between Vitamedic and the Associação Médicos Pela Vida (Doctors For Life Association) was proven, with the confirmation of the company’s director in testimony to the parliamentary inquiry commission, CPI of Covid, in the Federal Senate, that he invested R$717,000 in advertising the treatment.

“It is evidenced that the ‘pro-life manifest’ was an illicit mechanism of propaganda of the laboratory manufacturer of medicine, serving the defendant the sad role of a stooge for improper purposes and violators of fundamental value, the protection of public health.”

“[…] The only and pure illicit publicity of medication, due to the risks of its irrational use, already represents an affliction to public health, and its essentiality imposes the due compensation”, noted the magistrate.

The decision also affirms that Anvisa had a “mistaken action” and “omission” in the inspection of the “early treatment”, having avoided all the time to apply its norms about medicine advertising.

However, it states that the amount of compensation in the sentence exceeds what could be imposed by the Agency.

“Therefore, the judge understood to have lost object to the part in which the MPF asked Anvisa to take the appropriate measures to exercise its police power and punish undue advertising,” said the MPF.

The report sought the people cited in the decision but have not yet commented.

OVER 2,000 DOCTORS SIGNED A MANIFESTO

The Doctors for Life group emerged at the beginning of the Covid-19 pandemic to ensure that patients had the option of early treatment, in-home treatment so that they would seek healthcare only after symptoms had developed.

In 2021, the group published a manifesto signed by 2,122 physicians.

It cited scientific and clinical evidence to advocate using a cocktail of drugs to prevent patients from progressing to more severe stages of Covid-19.

Among the research cited by the manifesto was a survey conducted by 23 scientists in one of medicine’s most prestigious journals, The American Journal of Medicine, which stated that not a single drug but a set of drugs would have been effective in some cases in preventing further hospitalizations and deaths.

“The early approach is not only about the use of one or another drug, but the correct combination of medications such as hydroxychloroquine, ivermectin, bromhexine, azithromycin, zinc, vitamin D, anti-coagulants, among others, besides corticoids that have a right moment to be used in the inflammatory phases of the disease, always observing the adequacy of the combinations to the state and evolution of each patient, who will be followed extensively including the performance of tests as needed, and the recommendation of non-pharmacological interventions, such as physiotherapy, said the manifesto at the time.”

According to the group, using the cocktail of drugs would decrease the number of hospitalizations, reduce the burden on the hospital system, prevent post-infection complications, and reduce the number of deaths.

With information from Gazeta do Povo

News Brazil, English news Brazil, Brazilian Judiciary, Covid-19

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.